Wockhardt Limited Logo

Wockhardt Limited

WOCKPHARMA.NS

(1.0)
Stock Price

1.170,15 INR

-6.41% ROA

-10.1% ROE

-42.8x PER

Market Cap.

146.806.671.000,00 INR

65.08% DER

0% Yield

-11.86% NPM

Wockhardt Limited Stock Analysis

Wockhardt Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Wockhardt Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

The stock's ROE indicates a negative return (-39.72%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (0%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-1.884), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Wockhardt Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Wockhardt Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Wockhardt Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Wockhardt Limited Revenue
Year Revenue Growth
2005 14.130.350.000
2006 17.290.390.000 18.28%
2007 26.531.540.000 34.83%
2008 35.925.590.000 26.15%
2009 45.014.220.000 20.19%
2010 37.512.390.000 -20%
2011 46.138.000.000 18.7%
2012 56.094.200.000 17.75%
2013 48.303.600.000 -16.13%
2014 44.815.400.000 -7.78%
2015 44.614.300.000 -0.45%
2016 40.146.100.000 -11.13%
2017 39.369.000.000 -1.97%
2018 41.399.400.000 4.9%
2019 28.330.300.000 -46.13%
2020 26.992.100.000 -4.96%
2021 32.100.000.000 15.91%
2022 26.510.000.000 -21.09%
2023 30.120.000.000 11.99%
2023 27.980.000.000 -7.65%
2024 29.560.000.000 5.35%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Wockhardt Limited Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 537.900.000 100%
2012 8.270.700.000 93.5%
2013 4.030.400.000 -105.21%
2014 4.887.000.000 17.53%
2015 9.955.200.000 50.91%
2016 3.971.300.000 -150.68%
2017 2.872.000.000 -38.28%
2018 2.908.600.000 1.26%
2019 2.080.900.000 -39.78%
2020 1.724.500.000 -20.67%
2021 1.430.000.000 -20.59%
2022 1.410.000.000 -1.42%
2023 0 0%
2023 1.320.000.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Wockhardt Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 89.920.000
2006 116.950.000 23.11%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 2.673.200.000 100%
2012 1.020.400.000 -161.98%
2013 795.700.000 -28.24%
2014 1.399.600.000 43.15%
2015 2.060.900.000 32.09%
2016 3.031.500.000 32.02%
2017 2.692.500.000 -12.59%
2018 2.235.000.000 -20.47%
2019 1.024.000.000 -118.26%
2020 1.353.000.000 24.32%
2021 1.480.000.000 8.58%
2022 1.100.000.000 -34.55%
2023 0 0%
2023 1.050.000.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Wockhardt Limited EBITDA
Year EBITDA Growth
2005 3.631.280.000
2006 4.574.730.000 20.62%
2007 6.555.500.000 30.22%
2008 8.604.800.000 23.82%
2009 8.598.170.000 -0.08%
2010 9.246.290.000 7.01%
2011 14.622.300.000 36.77%
2012 20.873.000.000 29.95%
2013 10.641.100.000 -96.15%
2014 7.462.800.000 -42.59%
2015 5.580.000.000 -33.74%
2016 796.800.000 -600.3%
2017 461.300.000 -72.73%
2018 1.247.500.000 63.02%
2019 1.325.300.000 5.87%
2020 -203.500.000 751.25%
2021 3.010.000.000 106.76%
2022 2.230.000.000 -34.98%
2023 3.840.000.000 41.93%
2023 1.560.000.000 -146.15%
2024 3.680.000.000 57.61%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Wockhardt Limited Gross Profit
Year Gross Profit Growth
2005 8.358.990.000
2006 10.611.900.000 21.23%
2007 16.604.020.000 36.09%
2008 22.521.240.000 26.27%
2009 25.288.850.000 10.94%
2010 22.350.170.000 -13.15%
2011 27.759.300.000 19.49%
2012 38.618.600.000 28.12%
2013 30.241.100.000 -27.7%
2014 29.940.600.000 -1%
2015 28.572.200.000 -4.79%
2016 23.525.400.000 -21.45%
2017 21.393.700.000 -9.96%
2018 23.253.100.000 8%
2019 16.295.800.000 -42.69%
2020 15.637.200.000 -4.21%
2021 19.430.000.000 19.52%
2022 15.400.000.000 -26.17%
2023 18.640.000.000 17.38%
2023 7.810.000.000 -138.67%
2024 8.480.000.000 7.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Wockhardt Limited Net Profit
Year Net Profit Growth
2005 3.319.130.000
2006 3.470.940.000 4.37%
2007 3.858.140.000 10.04%
2008 -1.388.580.000 377.85%
2009 -10.006.630.000 86.12%
2010 905.190.000 1205.47%
2011 3.427.100.000 73.59%
2012 15.946.900.000 78.51%
2013 8.407.100.000 -89.68%
2014 4.049.100.000 -107.63%
2015 3.256.600.000 -24.34%
2016 -1.957.200.000 266.39%
2017 -6.083.000.000 67.83%
2018 -1.945.300.000 -212.7%
2019 -1.379.500.000 -41.01%
2020 -2.967.300.000 53.51%
2021 -2.790.000.000 -6.35%
2022 -6.210.000.000 55.07%
2023 -3.080.000.000 -101.62%
2023 -4.630.000.000 33.48%
2024 -560.000.000 -726.79%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Wockhardt Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 22
2006 20 -5%
2007 32 37.5%
2008 -12 390.91%
2009 -84 86.9%
2010 8 1300%
2011 29 75%
2012 134 79.1%
2013 71 -91.43%
2014 34 -112.12%
2015 21 -65%
2016 -16 225%
2017 -51 68%
2018 -16 -212.5%
2019 -11 -45.45%
2020 -25 54.17%
2021 -23 -4.35%
2022 -43 46.51%
2023 -21 -104.76%
2023 -32 34.38%
2024 -4 -966.67%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Wockhardt Limited Free Cashflow
Year Free Cashflow Growth
2005 305.450.000
2006 -823.890.000 137.07%
2007 411.430.000 300.25%
2008 -5.593.110.000 107.36%
2009 -2.477.930.000 -125.72%
2010 3.413.860.000 172.58%
2011 8.668.000.000 60.62%
2012 11.909.700.000 27.22%
2013 10.137.800.000 -17.48%
2014 -855.500.000 1285.01%
2015 -4.203.300.000 79.65%
2016 -6.800.900.000 38.19%
2017 -2.389.700.000 -184.59%
2018 -915.500.000 -161.03%
2019 4.765.800.000 119.21%
2020 -4.530.500.000 205.19%
2021 2.010.000.000 325.4%
2022 -560.000.000 458.93%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Wockhardt Limited Operating Cashflow
Year Operating Cashflow Growth
2005 2.046.550.000
2006 1.885.400.000 -8.55%
2007 3.772.080.000 50.02%
2008 1.245.040.000 -202.97%
2009 -1.925.330.000 164.67%
2010 6.418.070.000 130%
2011 11.843.400.000 45.81%
2012 15.324.000.000 22.71%
2013 14.762.900.000 -3.8%
2014 3.549.600.000 -315.9%
2015 716.100.000 -395.68%
2016 -2.694.700.000 126.57%
2017 684.400.000 493.73%
2018 1.833.200.000 62.67%
2019 6.489.600.000 71.75%
2020 -2.873.200.000 325.87%
2021 4.130.000.000 169.57%
2022 1.530.000.000 -169.93%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Wockhardt Limited Capital Expenditure
Year Capital Expenditure Growth
2005 1.741.100.000
2006 2.709.290.000 35.74%
2007 3.360.650.000 19.38%
2008 6.838.150.000 50.85%
2009 552.600.000 -1137.45%
2010 3.004.210.000 81.61%
2011 3.175.400.000 5.39%
2012 3.414.300.000 7%
2013 4.625.100.000 26.18%
2014 4.405.100.000 -4.99%
2015 4.919.400.000 10.45%
2016 4.106.200.000 -19.8%
2017 3.074.100.000 -33.57%
2018 2.748.700.000 -11.84%
2019 1.723.800.000 -59.46%
2020 1.657.300.000 -4.01%
2021 2.120.000.000 21.83%
2022 2.090.000.000 -1.44%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Wockhardt Limited Equity
Year Equity Growth
2005 8.161.040.000
2006 10.662.880.000 23.46%
2007 12.735.610.000 16.28%
2008 10.177.280.000 -25.14%
2009 8.352.710.000 -21.84%
2010 11.264.280.000 25.85%
2011 14.710.200.000 23.43%
2012 27.041.800.000 45.6%
2013 37.176.400.000 27.26%
2014 38.593.000.000 3.67%
2015 43.427.800.000 11.13%
2016 37.186.500.000 -16.78%
2017 31.978.800.000 -16.28%
2018 30.046.300.000 -6.43%
2019 30.574.600.000 1.73%
2020 37.602.500.000 18.69%
2021 42.020.000.000 10.51%
2022 36.620.000.000 -14.75%
2023 36.620.000.000 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Wockhardt Limited Assets
Year Assets Growth
2005 21.489.130.000
2006 37.142.240.000 42.14%
2007 51.530.890.000 27.92%
2008 67.280.740.000 23.41%
2009 57.256.810.000 -17.51%
2010 58.885.650.000 2.77%
2011 62.538.400.000 5.84%
2012 60.400.500.000 -3.54%
2013 66.220.200.000 8.79%
2014 69.388.800.000 4.57%
2015 79.521.600.000 12.74%
2016 89.686.900.000 11.33%
2017 81.620.400.000 -9.88%
2018 78.311.000.000 -4.23%
2019 81.789.100.000 4.25%
2020 77.726.900.000 -5.23%
2021 82.430.000.000 5.71%
2022 76.830.000.000 -7.29%
2023 76.490.000.000 -0.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Wockhardt Limited Liabilities
Year Liabilities Growth
2005 13.328.090.000
2006 26.479.360.000 49.67%
2007 38.795.280.000 31.75%
2008 57.103.460.000 32.06%
2009 48.904.100.000 -16.77%
2010 47.621.370.000 -2.69%
2011 47.828.200.000 0.43%
2012 33.358.700.000 -43.38%
2013 29.043.800.000 -14.86%
2014 30.795.800.000 5.69%
2015 36.093.800.000 14.68%
2016 52.500.400.000 31.25%
2017 49.641.600.000 -5.76%
2018 48.264.700.000 -2.85%
2019 51.214.500.000 5.76%
2020 40.124.400.000 -27.64%
2021 40.410.000.000 0.71%
2022 40.210.000.000 -0.5%
2023 39.870.000.000 -0.85%

Wockhardt Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
188.59
Net Income per Share
-22.36
Price to Earning Ratio
-42.8x
Price To Sales Ratio
5.07x
POCF Ratio
44.49
PFCF Ratio
44.49
Price to Book Ratio
4.37
EV to Sales
5.71
EV Over EBITDA
65.25
EV to Operating CashFlow
50.02
EV to FreeCashFlow
50.02
Earnings Yield
-0.02
FreeCashFlow Yield
0.02
Market Cap
146,81 Bil.
Enterprise Value
165,08 Bil.
Graham Number
331.91
Graham NetNet
-171.61

Income Statement Metrics

Net Income per Share
-22.36
Income Quality
-0.71
ROE
-0.1
Return On Assets
-0.04
Return On Capital Employed
0.01
Net Income per EBT
1.11
EBT Per Ebit
-9.94
Ebit per Revenue
0.01
Effective Tax Rate
-0.14

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.44
Operating Profit Margin
0.01
Pretax Profit Margin
-0.11
Net Profit Margin
-0.12

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
21.51
Free CashFlow per Share
21.51
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.01
Return on Tangible Assets
-0.06
Days Sales Outstanding
77.97
Days Payables Outstanding
172.06
Days of Inventory on Hand
143.75
Receivables Turnover
4.68
Payables Turnover
2.12
Inventory Turnover
2.54
Capex per Share
0

Balance Sheet

Cash per Share
37,22
Book Value per Share
238,72
Tangible Book Value per Share
89.18
Shareholders Equity per Share
218.97
Interest Debt per Share
161.99
Debt to Equity
0.65
Debt to Assets
0.29
Net Debt to EBITDA
7.22
Current Ratio
0.74
Tangible Asset Value
13,68 Bil.
Net Current Asset Value
-19,14 Bil.
Invested Capital
38850000000
Working Capital
-7,18 Bil.
Intangibles to Total Assets
0.3
Average Receivables
3,09 Bil.
Average Payables
3,83 Bil.
Average Inventory
3200000000
Debt to Market Cap
0.15

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Wockhardt Limited Dividends
Year Dividends Growth
2003 7
2004 8 14.29%
2005 5 -40%
2006 5 0%
2007 14 61.54%
2008 3 -550%
2013 10 80%
2014 25 60%
2016 10 -150%

Wockhardt Limited Profile

About Wockhardt Limited

Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.

CEO
Dr. Habil Fakhruddin Khorakiwa
Employee
2.386
Address
Wockhardt Towers
Mumbai, 400051

Wockhardt Limited Executives & BODs

Wockhardt Limited Executives & BODs
# Name Age
1 Mr. Zoher T. Sihorwala
Head of Global Regulatory Affairs
70
2 Mr. Neeraj Agarwal
Chief Human Resource Officer
70
3 Ms. Debolina Partap
Senior Vice President of Legal
70
4 Mr. Prakash Gupta
President of Supply Chain
70
5 Mr. Deepak R. Madnani
Chief Financial Officer
70
6 Dr. Mahesh Vithalbhai Patel
Chief Scientific Officer of New Drug Discovery
70
7 Mr. Anil V. Kamath AMRSH (Lon.), BCom (Hons), MBIM (Lon.), MIMA
Senior Vice President of Business Development
70
8 Dr. Habil Fakhruddin Khorakiwala
Founder & Executive Chairman
70
9 Dr. Murtaza Habil Khorakiwala
MD & Executive Director
70
10 Dr. Huzaifa Habil Khorakiwala
Executive Director
70

Wockhardt Limited Competitors

Ajanta Pharma Limited Logo
Ajanta Pharma Limited

AJANTPHARM.NS

(3.2)
Torrent Pharmaceuticals Limited Logo
Torrent Pharmaceuticals Limited

TORNTPHARM.NS

(2.8)
Just Dial Limited Logo
Just Dial Limited

JUSTDIAL.NS

(2.2)